Akebia TherapeuticsAKBA
AKBA
About: Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Employees: 167
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
130% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 20
64% more capital invested
Capital invested by funds: $78.6M [Q3] → $129M (+$50.6M) [Q4]
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
6% more funds holding
Funds holding: 114 [Q3] → 121 (+7) [Q4]
2.85% more ownership
Funds ownership: 28.31% [Q3] → 31.16% (+2.85%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
56% less call options, than puts
Call options by funds: $335K | Put options by funds: $769K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
219%
upside
Avg. target
$6.50
246%
upside
High target
$7.50
299%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Jefferies Roger Song 0% 1-year accuracy 0 / 7 met price target | 219%upside $6 | Buy Initiated | 1 Apr 2025 |
Piper Sandler Allison Bratzel 50% 1-year accuracy 1 / 2 met price target | 219%upside $6 | Overweight Maintained | 14 Mar 2025 |
HC Wainwright & Co. Ed Arce 24% 1-year accuracy 9 / 38 met price target | 299%upside $7.50 | Buy Reiterated | 14 Mar 2025 |
Financial journalist opinion
Based on 12 articles about AKBA published over the past 30 days
Neutral
GlobeNewsWire
7 hours ago
Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve XOANACYL® (Ferric Citrate as Coordination Complex) for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease (CKD).
Neutral
GlobeNewsWire
23 hours ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 73,325 shares of Akebia's common stock on March 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 week ago
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025
CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25), which will take place in Boston, MA from April 10-13, 2025.
Negative
Zacks Investment Research
1 week ago
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering
AKBA's shares fell after announcing the pricing of its secondary issue of shares, which were at a discount to the previous closing price.
Negative
Benzinga
2 weeks ago
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Thursday.
Neutral
GlobeNewsWire
2 weeks ago
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of its underwritten public offering (the “Offering”) of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. All shares are being offered by Akebia. The gross proceeds to Akebia from the Offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be $50.0 million. In addition, Akebia has granted the underwriters a 30-day option to purchase up to 3,750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on March 21, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
2 weeks ago
Akebia Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has commenced an underwritten public offering (the “Offering”). All shares are being offered by Akebia. In addition, Akebia expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the Offering at the public offering price, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.
Neutral
Seeking Alpha
3 weeks ago
Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, IR John Butler - CEO Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial & Business Officer Conference Call Participants Allison Bratzel - Piper Sandler Julian Harrison - BTIG Ed Arce - H.C. Wainwright Operator Good day, and welcome to Akebia's Fourth Quarter 2024 Financial Results Call.
Negative
Zacks Investment Research
3 weeks ago
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.
Neutral
GlobeNewsWire
3 weeks ago
Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update
Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 million Cash resources and cash from operations expected to fund current operating plan for at least two years Akebia to Host Conference Call at 8:00 a.m. ET on March 13, 2025 CAMBRIDGE, Mass.
Charts implemented using Lightweight Charts™